iShares US Pharma

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Bristol Myers Squibb Partners with Anthropic and Tempus AI to Build AI Drug Development Collaboration

Eli Lilly Acquires Engage Bio to Accelerate Non-Viral Gene Drug Development

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

Pfizer and Sarah Cannon Institute Announce Strategic Oncology Research Collaboration

CDD and Eli Lilly Collaborate to Integrate TuneLab AI Platform into CDD Vault

Bristol Myers Squibb Provides Anthropic's Claude to 30,000 Employees

Marble Harbor Increases Pfizer Stake by 13.4% to $11.1M as Q4 Earnings Beat Expectations

Pfizer Advances Key Pediatric Pneumococcal Vaccine Project Following Strong Phase II Results

Fideuram Intesa Sanpaolo Acquires 84,300 JNJ Shares Worth $17.4M in Q4

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

Elanco EVP Rajeev A. Modi Buys Nearly 5,000 Shares, Total Holdings Rise to Approx 160k

Elanco CEO Jeffrey N. Simmons Buys 4,971 Shares and Receives 142 DSUs

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UBS Upgrades Jazz Pharma to Buy, Raises Price Target to $307

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Pinned News

置顶新闻

BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary

PHGE

DFNS

SBIO

LABU

IBBQ

BiomX Inc. reported a net loss of $19.14M for Q1 2026, up from $7.66M in Q1 2025, as it shifts focus from biopharma to defense technology. The company acquired Zorronet and a 60% stake in DFSL, launching a new unit, X Security. Revenue contributions from these acquisitions are expected starting Q2 2026, with active projects underway with major clients.

TradingView

T3 Defense

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Elbit

RLAY

ARKG

Relay Therapeutics' drug zovegalisib shows promise in treating vascular anomalies, achieving a 60% response rate in a mid-stage trial. Most patients reported symptom improvement, and the drug appears safe for chronic use. Relay's shares rose by 10% following the announcement. Analysts predict zovegalisib could generate $2.8 billion in peak annual sales, highlighting its potential as a leading treatment in this area. Further testing is planned, with results expected by year-end.

biopharmadive

Relay Therapeutics

Health Care Select Sector SPDR

iShares Global Healthcare

VG Health

Ark Genomic Revolution ETF

NOVARTIS AG

Novartis AG

Relay drug shows early promise against rare blood vessel diseases

Dyne Therapeutics has granted inducement equity awards to 17 new hires, including 296,500 stock options priced at the May 20 Nasdaq closing price. The options have a 10-year term and vest over four years, with 25% vesting on the first anniversary. Additionally, 94,100 restricted stock units will vest in four equal annual installments. These awards are part of Dyne's 2024 Inducement Stock Incentive Plan.

PUBT

Dyne Therapeutics

Dyne Therapeutics grants inducement awards to 17 hires, including 296,500 stock options

TXMD

TherapeuticsMD Inc. (TXMD) shares rose 1.96% to $2.08 on a strong trading day, marking the fourth consecutive day of gains. The NASDAQ Composite Index increased by 1.54%, while the Dow Jones Industrial Average rose 1.31%. TXMD remains 29.49% below its 52-week high of $2.95. In contrast, competitor AbbVie Inc. (ABBV) fell 0.68% to $212.30. Trading volume was below the 50-day average.

MarketWatch Automated

Therapeutics MD

NASDAQ Composite Index

Dow Jones Industrial Average

Abbvie

TherapeuticsMD Inc. Stock Outperforms Competitors On Strong Trading Day

NVAX

Novavax Inc. (NVAX) shares rose 4.16% to $9.27, outperforming competitors on a positive trading day. The NASDAQ Composite increased by 1.54%, while the Dow Jones rose 1.31%. Despite the gain, NVAX remains 22.56% below its 52-week high of $11.97. Competitors like Johnson & Johnson and Merck saw declines, while Pfizer experienced a slight increase. Trading volume reached 4.9 million, surpassing the 50-day average of 4.3 million.

Novavax

Johnson & Johnson

Pfizer

Merck

Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

ASPI

ASP has released an updated investor presentation as of May 20, 2026, which includes forward-looking statements and notes its non-filing status. The information is not filed under the Exchange Act or Securities Act and contains safe-harbor language regarding risks and uncertainties. ASP disclaims any obligation to update the presentation or revise the forward-looking statements.

ASP Isotopes

ASP Releases Updated Investor Presentation, Notes Forward-Looking Statements

Baxter International Inc. (BAX) shares rose 2.40% to $18.77 on a strong trading day, outperforming competitors like Medtronic PLC and Stryker Corp. The stock has gained for three consecutive days but remains 41.42% below its 52-week high of $32.04. The S&P 500 and Dow Jones also saw increases of 1.08% and 1.31%, respectively.

Baxter

iShares US Medical Devices

SPDR S&P Health Equip

S&P 500

Medtronic

Stryker

Becton Dickinson and

Factset Research

Baxter International Inc. Stock Outperforms Competitors On Strong Trading Day

VTRS

Viatris Inc. (VTRS) shares rose 2.60% to $16.59 on Wednesday, outperforming the market as the S&P 500 and Dow Jones increased by 1.08% and 1.31%, respectively. The stock remains 5.36% below its 52-week high of $17.53, achieved on May 14th, with trading volume at 11.4 million, surpassing its 50-day average of 11.2 million.

Viatris

Viatris Inc. Stock Rises Wednesday, Outperforms Market

INCY

Incyte Corp. (INCY) shares rose 1.55% to $97.08 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.08%, while the Dow Jones Industrial Average rose 1.31%. Incyte's stock remains 13.55% below its 52-week high of $112.29. Trading volume was 1.1 million, below the 50-day average of 1.5 million.

Incyte

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

SDEV

GELS

In Wednesday's after-market session, Liminatus Pharma (LIMN) surged 24.1% to $0.23, while BiomX (PHGE) rose 12.33% to $0.67. Jupiter Neurosciences (JUNS) and Stablecoin Development (SDEV) also saw gains of 12.19% and 11.18%, respectively. Conversely, HCW Biologics (HCWB) fell 15.6% to $2.05, and MetaVia (MTVA) dropped 9.0% to $2.63. Other notable losers included INVO Fertility (IVF) and Gelteq (GELS) with declines of 7.74% and 7.72%.

benzinga_article

Stablecoin Development

Gelteq

INVO Fertility

Jupiter Neurosciences

Liminatus Pharma

iShares US Healthcare Providers

SPDR S&P Health

Alps

Longeveron

Nanobiotix SA

LIMINATUS PHARMA INC C/WTS 30/04/2030 (TO PUR COM)

ALPS GROUP INC C/WTS (TO PUR ORD)

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's After-Market Session

REGN

Regeneron Pharmaceuticals Inc. (REGN) shares rose 3.24% to $649.76 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.08%, while the Dow Jones Industrial Average rose by 1.31%. Despite the gains, REGN remains 20.87% below its 52-week high of $821.11. Trading volume reached 1.1 million, surpassing its 50-day average of 754,984.

Regeneron Pharma

Amgen

Moderna

Gilead Sciences

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Merck & Co. Inc. (MRK) shares fell 1.09% to $113.00 on Wednesday, underperforming against competitors as the S&P 500 rose 1.08%. This decline ended a two-day winning streak, leaving the stock 9.70% below its 52-week high of $125.14. Trading volume was 9.0 million, slightly below the 50-day average of 9.3 million.

Eli Lilly

Merck & Co. Inc. Stock Underperforms Wednesday When Compared To Competitors

iShares US Pharma(IHE.US)